Analyst Coverage
The following organisations provide research coverage on Pharmaxis:
MST Access Services Pty Limited
Analyst: Chris Kallos
Senior Life Science Analyst
chris.kallos@mstaccess.com.au
MST Access initiated coverage on 1 November 2021
Read MST Access reports below:
| 12 November 2021 | New indication for PXS-5505 |
| 1 November 2021 | Initiation of Coverage |
Taylor Collison Ltd
Analyst: Dennis Hulme
Taylor Collison initiated coverage on 30 November 2021
For copies of current reports contact Taylor Collison.
| Initiation Report: Pharmaxis - Exploring Efficacy in Cancer and Fibrosis | 30 November 2021 |
Bioshares
Blake Industry and Market Analysis Pty Ltd
Editors: David Blake and Mark Pachacz (info@bioshares.com.au)
Read Bioshares most recent reports:
| 19 April 2021 |
Karst Peak Continues Investment in Austalia Biotech |
| 15 February 2021 |
Pharmaxis Makes First Commercial Bronchitol Shipment to USA |
| 3 November 2020 |
Bronchitol FDA Approval a Turning Point for Pharmaxis |
| 7 September 2020 |
Boehringer Ends Development of Pharmaxis Compound |
| 10 August 2020 |
A Big Six Months Ahead for Pharmaxis |
| 4 May 2020 |
Pharmaxis - Multiple Assets to Drive Value |
| 24 February 2020 |
Pharmaxis Remains Confident of Securing LOXL2 Deal |
| 24 December 2019 |
Top Six Stock Picks – 2020 |
| 19 December 2019 |
Boehringer Ingelheim Discontinues |
| 28 October 2019 |
PXS Completes Phase Ia Trial of PXS5505A |
| 24 June 2019 |
Pharmaxis' Bronchitol Edges Closer to FDA Approval |
| 13 May 2019 |
Pharmaxis Gains Positive Vote for Bronchitol in USA |
| 29 April 2019 |
Pharmaxis Update |
| 25 February 2019 |
Pharmaxis Tackles the Intractable |
| 25 January 2019 |
Pharmaxis' LOXL2 Program Ready for a Deal |
| 10 December 2018 |
Pharmaxis Investor Briefing Summary |
| 12 October 2018 |
More Positive Phase I Data from LOXL2 Program |
| 13 August 2018 | Pharmaxis strengthens balance sheet ahead of LOXL2 licensing deal |
| 20 July 2018 | Interview with Dr Kathleen Metters |
| 8 May 2018 |
Pharmaxis – a drug developer with a deal making record |
| 5 February 2018 | A busy year for Pharmaxis – multiple trial readouts ahead |
| 8 September 2017 |
Pharmaxis – Boehringer selects diabetic retinopathy as second indication |
| 4 September 2017 |
Pharmaxis' partner starts phase II NASH trial |
| 24 March 2017 |
Three share price drivers for Pharmaxis |
| 28 October 2016 | Pharmaxis. All attention on NASH for Pharmaxis |
Emerald Financial
Analyst: Alfred Chan
Read Emerald Financial most recent reports:
| 18 May 2021 | Initial report |
Bell Potter Securities Limited
Analyst: Tanushree Jain (tnjain@bellpotter.com.au)
Bell Potter initiated coverage on 8 December 2017.
For copies of current reports contact Bell Potter.
| 13 February 2021 | |
| 7 January 2021 |
FDA approval for Bronchitol revamps the business, improves outlook |
| 7 September 2020 |
BI terminates agreement, discontinues |
| 19 August 2020 | |
| 13 August | |
| 5 August 2020 | |
| 22 May 2020 | |
| 13 February 2020 | |
| 6 February 2020 | |
| 25 November 2019 | |
| 16 August 2019 | |
| 30 July 2019 | |
| 24 June 2019 |
FDA Issues CRL on Bronchitol - approval now expected in early 2020 |
| 15 May 2019 |
Bronchitol gets positive recommendation from Adcom by a narrow majority
|
| 15 February 2019 | |
| 30 April 2018 |
Interim data from Phase 1 LOXL-2 program strengthen partnering prospects |
| 16 February 2018 | 1H18 Results - no material change from unaudited results released earlier |
| 1 February 2018 | |
| 11 January 2018 |
BI milestone strengthens balance sheet, LOXL-2 moves into the clinic |
| 8 December 2017 |
Emerging as a key player in multi-billion dollar NASH market |
